- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07949422
Application of 177Lu-SSTR2 Antagonist Therapy in Advanced Neuroendocrine Tumors
Safety, Feasibility, and Preliminary Efficacy of 177Lu-SSTR2 Antagonist Peptide Receptor Radionuclide Therapy in Patients With Advanced Neuroendocrine Tumors
This single-center, prospective, single-arm exploratory study will evaluate the safety, feasibility, and preliminary effectiveness of lutetium-177 (177Lu)-labeled SSTR2 antagonist therapy in two patients with advanced gastroenteropancreatic neuroendocrine tumors. Eligible patients will have grade 1-2, somatostatin receptor-positive tumors that cannot be surgically removed or have spread, and have progressed despite somatostatin analogue therapy. Participants will receive 3-4 intravenous treatments, generally every 8 weeks, at an activity not exceeding 7.4 GBq per treatment, with amino acids for kidney protection. Side effects, blood counts, liver and kidney function, and treatment completion will be assessed. Tumor response, disease progression, and quality of life will also be evaluated. Follow-up will continue for 2 years after the last treatment.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Xin Liu, M.D.
- Phone Number: 13269997223
- Email: liux0077@163.com
Study Locations
-
-
Chao Yang
-
Beijing, Chao Yang, China, 100021
- Recruiting
- National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-75 years.
- Unresectable or metastatic, SSTR-positive grade 1-2 gastroenteropancreatic neuroendocrine tumors.
- Progression after ≥12 weeks of somatostatin analogue therapy, with no more suitable standard treatment.
- Measurable disease per RECIST 1.1.
- ECOG 0-2, life expectancy ≥3 months, and adequate bone marrow, liver, and kidney function.
- Written informed consent.
Exclusion Criteria:
- Previous PRRT, another malignancy, or severe organ dysfunction.
- Pregnancy, breastfeeding, or planned pregnancy.
- Relevant drug allergy or contraindication to contrast imaging.
- Recent anticancer or investigational treatment, radiotherapy, or major surgery within protocol-defined exclusion periods.
- Unresolved treatment toxicity or inability to suspend prohibited medications.
- Inability to complete treatment or follow-up, or other conditions deemed unsuitable by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 177Lu-SSTR2 Antagonist Therapy
Participants will receive 177Lu-SSTR2 antagonist by intravenous infusion over 30-60 minutes for 3-4 cycles, generally every 8 weeks, at an activity not exceeding 7.4 GBq per cycle |
177Lu-SSTR2 antagonist will be administered by intravenous infusion over 30-60 minutes, at an activity not exceeding 7.4 GBq per cycle, for 3-4 cycles generally 8 weeks apart. Activity and intervals may be adjusted according to tolerability and organ function. Amino acids will be administered for kidney protection. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Treatment-Related Adverse Events
Time Frame: From the first dose through 2 years after the last dose.
|
Number and percentage of participants with treatment-related adverse events, graded using CTCAE 5.0. |
From the first dose through 2 years after the last dose.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response Rate
Time Frame: Approximately 6 weeks after each cycle and 8-12 weeks after the last dose
|
Percentage of evaluable participants achieving a complete or partial response on CT or MRI according to RECIST 1.1. |
Approximately 6 weeks after each cycle and 8-12 weeks after the last dose
|
Collaborators and Investigators
Investigators
- Study Chair: Xuejuan Wang, M.D., Chinese Academy of Medical Sciences
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- NCC6604
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.